Last reviewed · How we verify
Cefadole — Competitive Intelligence Brief
phase 2
cefamandole
Solute carrier family 15 member 1
Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
Cefadole (CEFAMANDOLE). Cefadole works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.
Comparator set (2 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Cefadole TARGET | CEFAMANDOLE | phase 2 | cefamandole | Solute carrier family 15 member 1 | ||
| Cefadrox | CEFADROXIL | marketed | cefadroxil | Solute carrier family 15 member 1 | 1978-01-01 | |
| Kefadol | CEFAMANDOLE NAFATE | Eli Lilly | marketed | cefamandole nafate | Bacterial penicillin-binding protein | 1978-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (cefamandole class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Cefadole CI watch — RSS
- Cefadole CI watch — Atom
- Cefadole CI watch — JSON
- Cefadole alone — RSS
- Whole cefamandole class — RSS
Cite this brief
Drug Landscape (2026). Cefadole — Competitive Intelligence Brief. https://druglandscape.com/ci/cefamandole. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing